Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients

C1-inhibitor (C1-INH) is an important regulator of the complement, coagulation, fibrinolytic and contact systems. The quantity of protease/C1-INH complexes in the blood is proportional to the level of the in vivo activation of these four cascade-like plasma enzyme systems. Parallel determination of C1-INH-containing activation complexes could be important to understand the regulatory role of C1-INH in diseases such as hereditary angioedema (HAE) due to C1-INH deficiency (C1-INH-HAE). We developed in-house ELISAs to measure the concentration of complexes of C1-INH formed with active proteases: C1r, C1s, MASP-1, MASP-2, plasma kallikrein, factor XIIa, factor XIa, and thrombin, as well as to determine total and functionally active C1-INH. We measured the concentration of the complexes in EDTA plasma from 6 healthy controls, from 5 with type I and 5 with type II C1-INH-HAE patients during symptom-free periods and from five patients during HAE attacks. We also assessed the concentration of these complexes in blood samples taken from one C1-INH-HAE patient during the kinetic follow-up of a HAE attack. The overall pattern of complexed C1-INH was similar in controls and C1-INH-HAE patients. C1-INH formed the highest concentration complexes with C1r and C1s. We observed higher plasma kallikrein/C1-INH complex concentration in both type I and type II C1-INH-HAE, and higher concentration of MASP-1/C1-INH, and MASP-2/C1-INH complexes in type II C1-INH-HAE patients compared to healthy controls and type I patients. Interestingly, none of the C1-INH complex concentrations changed significantly during HAE attacks. During the kinetic follow-up of an HAE attack, the concentration of plasma kallikrein/C1-INH complex was elevated at the onset of the attack. In parallel, C1r, FXIIa and FXIa complexes of C1-INH also tended to be elevated, and the changes in the concentrations of the complexes followed rather rapid kinetics. Our results suggest that the complement classical pathway plays a critical role in the metabolism of C1-INH, however, in C1-INH-HAE, contact system activation is the most significant in this respect. Due to the fast changes in the concentration of complexes, high resolution kinetic follow-up studies are needed to clarify the precise molecular background of C1-INH-HAE pathogenesis.

[1]  Z. Nemeth,et al.  MASP-1 Increases Endothelial Permeability , 2019, Front. Immunol..

[2]  H. Farkas,et al.  Complete kinetic follow‐up of symptoms and complement parameters during a hereditary angioedema attack , 2018, Allergy.

[3]  M. Triggiani,et al.  Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes , 2018, International Archives of Allergy and Immunology.

[4]  T. Renné,et al.  Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. , 2016, The Journal of allergy and clinical immunology.

[5]  B. Nilsson,et al.  The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation , 2016, Journal of thrombosis and haemostasis : JTH.

[6]  Anna E. Engberg,et al.  Reciprocal relationship between contact and complement system activation on artificial polymers exposed to whole human blood. , 2016, Biomaterials.

[7]  K. Skjødt,et al.  The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema , 2015, The Journal of Immunology.

[8]  A. Kaplan,et al.  Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. , 2014, Advances in immunology.

[9]  J. Dobó,et al.  C1 inhibitor: quantification and purification. , 2014, Methods in molecular biology.

[10]  P. Gál,et al.  The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not. , 2013, Molecular immunology.

[11]  S. Zeerleder C1-inhibitor: more than a serine protease inhibitor. , 2011, Seminars in thrombosis and hemostasis.

[12]  K. Kekesi,et al.  Cleavage of Kininogen and Subsequent Bradykinin Release by the Complement Component: Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 , 2011, PloS one.

[13]  H. Farkas,et al.  Parameters of the classical complement pathway predict disease severity in hereditary angioedema. , 2011, Clinical immunology.

[14]  H. Farkas,et al.  Management of upper airway edema caused by hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[15]  M. Cicardi,et al.  Angioedema due to C1 inhibitor deficiency in 2010 , 2010, Internal and emergency medicine.

[16]  Bo Nilsson,et al.  Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. , 2009, Biomaterials.

[17]  P. Gál,et al.  Complement Protease MASP-1 Activates Human Endothelial Cells: PAR4 Activation Is a Link between Complement and Endothelial Function1 , 2009, The Journal of Immunology.

[18]  E. Vogler,et al.  Contact activation of blood-plasma coagulation. , 2009, Biomaterials.

[19]  C. Hack,et al.  Structure and function of C1-inhibitor. , 2006, Immunology and allergy clinics of North America.

[20]  L. Gráf,et al.  Natural Substrates and Inhibitors of Mannan-Binding Lectin-Associated Serine Protease-1 and -2: A Study on Recombinant Catalytic Fragments 1 , 2003, The Journal of Immunology.

[21]  P. Patston,et al.  The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  C. Hack,et al.  In vitro interaction of C1-inhibitor with thrombin , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  P. Patston,et al.  The inhibition of TNK-t-PA by C1-inhibitor , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  M. Kojima,et al.  Activities of the MBL-associated serine proteases (MASPs) and their regulation by natural inhibitors. , 1999, Molecular immunology.

[25]  M. Walport,et al.  The Complement Factsbook , 1999 .

[26]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[27]  G. Elgue,et al.  Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. , 1998, Thrombosis research.

[28]  C. Feighery,et al.  Degradation of C1-Inhibitor by Plasmin: Implications for the Control of Inflammatory Processes , 1997, Molecular medicine.

[29]  T. Mollnes,et al.  Activation of the Complement, Coagulation, Fibrinolytic and Kallikrein–Kinin Systems During Attacks of Hereditary Angioedema , 1996, Immunopharmacology.

[30]  T. Mollnes,et al.  C3 is Activated in Hereditary Angioedema, and C1/C1‐Inhibitor Complexes Rise During Physical Stress in Untreated Patients , 1995, Scandinavian journal of immunology.

[31]  F. Pavalko,et al.  Vascular endothelial cell activation and permeability responses to thrombin. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[32]  C. Hack,et al.  Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. , 1995, Blood.

[33]  A. Eerenberg,et al.  Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.

[34]  C. Hack,et al.  Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. , 1993, Blood.

[35]  J. Beechem,et al.  Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. , 1991, Biochemistry.

[36]  G. Füst,et al.  Concentration of C1 inhibitor in sera of healthy blood donors as studied by immunoenzymatic assay. , 1991, Complement and inflammation.

[37]  R. Dwek,et al.  Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. , 1990, Journal of molecular biology.

[38]  E. Hack,et al.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. , 1990, The Journal of clinical investigation.

[39]  R. Colman,et al.  Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. , 1989, Blood.

[40]  V. Schumaker,et al.  Expression of hemolytically active human complement component C1r proenzyme in insect cells using a baculovirus vector. , 1989, Complement and inflammation.

[41]  C. Hack,et al.  Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. , 1988, Blood.

[42]  W. V. Van Nostrand,et al.  Functional and structural similarities between protease nexin I and C1 inhibitor. , 1988, The Journal of biological chemistry.

[43]  A. Kaplan,et al.  Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. , 1985, Blood.

[44]  S. Thorsen,et al.  Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. , 1984, Biochimica et biophysica acta.

[45]  B. Wüthrich,et al.  Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. , 1984, Complement.

[46]  A. Kaplan,et al.  Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. , 1983, The Journal of biological chemistry.

[47]  Robert B Sim,et al.  Interaction of 125I‐labelled complement subcomponents C r and C s with protease inhibitors in plasma , 1979, FEBS letters.

[48]  N. Cooper,et al.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. , 1975, The Journal of clinical investigation.

[49]  K.,et al.  Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. , 1973, The Journal of clinical investigation.

[50]  F. Rosen,et al.  Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. , 1971, The Journal of clinical investigation.

[51]  R. Colman,et al.  Interaction of plasma kallikrein with the C1 inhibitor. , 1970, Journal of immunology.

[52]  O. Ratnoff,et al.  THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR , 1969, The Journal of experimental medicine.

[53]  J. Pensky,et al.  Partial purification of a serum inhibitor of C'1-esterase. , 1961, The Journal of biological chemistry.